trending Market Intelligence /marketintelligence/en/news-insights/trending/n7lrspro_56htxddnonz8a2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Regulus pauses clinical activities, reduces workforce to preserve capital

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Regulus pauses clinical activities, reduces workforce to preserve capital

Regulus Therapeutics Inc. said it paused certain clinical activities and will lay off about 60% of its workforce.

The San Diego-based biopharmaceutical company paused recruitment activities for its RG-012, its potential treatment for Alport syndrome. A phase 1 trial of RGLS4326, another kidney disease drug, was paused.

Regulus expects the restructuring to yield over $20 million in annualized savings, extending its cash runway into mid-2019.

"I am very disappointed that we need to take these drastic steps to preserve our capital," company President and CEO Jay Hagan said in a news release.

Regulus is in talks to potentially restructure a partnership with Paris-based Sanofi.